{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:20Z","timestamp":1791231440212,"version":"4.1.0"},"reference-count":54,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Both clinical and experimental evidence illustrate that p190 and p210 BCR\/ABL oncogenic tyrosine kinases induce resistance to DNA damage and confer an intrinsic genetic instability. Here, we investigated whether BCR\/ABL expression could modulate nucleotide excision repair (NER). We found that ectopic expression of p210 BCR\/ABL in murine lymphoid BaF3 cell line inhibited NER activity in vitro, promoting hypersensitivity of these cells to ultraviolet (UV) treatment and facilitating a mutator phenotype. However, expression of p210 BCR\/ABL in human and murine myeloid cell lines and primary bone marrow cells resulted in the increased NER activity and resistance to UV irradiation. The ABL tyrosine kinase inhibitor STI571 reversed these effects, showing that p210 BCR\/ABL tyrosine kinase activity is responsible for deregulation of NER. Hypoactivity of NER in p210 BCR\/ABL-positive lymphoid cells was accompanied by the decreased interaction between proliferating cell nuclear antigen (PCNA) and xeroderma pigmentosum group B (XPB); conversely, this interaction was enhanced in p210 BCR\/ABL-positive myeloid cells. p190 BCR\/ABL did not affect NER in lymphoid and myeloid cells. In summary, our study suggests that p210 BCR\/ABL reduced NER activity in lymphoid cells, leading to hypersensitivity to UV and mutagenesis. In contrast, p210 BCR\/ABL expression in myeloid cells facilitated NER and induced resistance to UV. (Blood. 2003;102:2632-2637)<\/jats:p>","DOI":"10.1182\/blood-2002-10-3207","type":"journal-article","created":{"date-parts":[[2003,6,30]],"date-time":"2003-06-30T20:15:24Z","timestamp":1057004124000},"page":"2632-2637","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":67,"title":["p210 BCR\/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation"],"prefix":"10.1182","volume":"102","author":[{"given":"Yvan","family":"Canitrot","sequence":"first","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Falinski","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Louat","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Cazaux","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Se\u0301bastien","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Lautier","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Skorski","sequence":"additional","affiliation":[{"name":"From the Genetic Instability and Cancer, Institut de Pharmacologie et Biologie Structurale, Toulouse, France; Center for Biotechnology, Temple University, Philadelphia, PA; Institut National de la Sante\u0301 et de la Recherche Me\u0301dicale (INSERM) U563, Institut Claudius Regaud, Toulouse, France; and Service d'Hematologie, Centre Hospitalie\u0300r Universitaire Purpan, Toulouse, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021221595894800_REF1","doi-asserted-by":"crossref","unstructured":"Clark SS, McLaughlin J, Timmons M, et al. Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL). Science. 1988;239: 775-777.","DOI":"10.1126\/science.3422516"},{"key":"2020021221595894800_REF2","doi-asserted-by":"crossref","unstructured":"Shtivelman E, Lifshitz B, Gale RP, Roe BA, Canaani E. Alternative splicing of RNAs transcribed from the human abl gene and from the bcr-abl fused gene. Cell. 1986;47: 277-284.","DOI":"10.1016\/0092-8674(86)90450-2"},{"key":"2020021221595894800_REF3","doi-asserted-by":"crossref","unstructured":"Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med. 2003;138: 819-830.","DOI":"10.7326\/0003-4819-138-10-200305200-00010"},{"key":"2020021221595894800_REF4","doi-asserted-by":"crossref","unstructured":"Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillieres Clin Haematol. 1997;10: 223-231.","DOI":"10.1016\/S0950-3536(97)80004-2"},{"key":"2020021221595894800_REF5","doi-asserted-by":"crossref","unstructured":"Amarante-Mendes GP, Naekyung Kim C, Liu L, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91: 1700-1705.","DOI":"10.1182\/blood.V91.5.1700"},{"key":"2020021221595894800_REF6","doi-asserted-by":"crossref","unstructured":"Masumoto N, Nakano S, Fujishima H, Kohno K, Niho Y. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells. Int J Cancer. 1999;80: 731-737.","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H"},{"key":"2020021221595894800_REF7","doi-asserted-by":"crossref","unstructured":"Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000;22: 673-680.","DOI":"10.1002\/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A"},{"key":"2020021221595894800_REF8","doi-asserted-by":"crossref","unstructured":"Bedi A, Barber JP, Bedi GC, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2\/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86: 1148-1158.","DOI":"10.1182\/blood.V86.3.1148.1148"},{"key":"2020021221595894800_REF9","doi-asserted-by":"crossref","unstructured":"Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E. BCR-ABL delays apoptosis upstream of procaspase-3 activation. Blood. 1998;91: 2415-2422.","DOI":"10.1182\/blood.V91.7.2415"},{"key":"2020021221595894800_REF10","doi-asserted-by":"crossref","unstructured":"Maru Y, Bergmann E, Coin F, Egly JM, Shibuya M. TFIIH functions are altered by the P210BCRABL oncoprotein produced on the Philadelphia chromosome. Mutat Res. 2001;483: 83-88.","DOI":"10.1016\/S0027-5107(01)00229-9"},{"key":"2020021221595894800_REF11","unstructured":"Nishii K, Kabarowski JH, Gibbons DL, et al. ts BCR-ABL kinase activation confers increased resistance to genotoxic damage via cell cycle block. Oncogene. 1996;13: 2225-2234."},{"key":"2020021221595894800_REF12","doi-asserted-by":"crossref","unstructured":"Slupianek A, Schmutte C, Tombline G, et al. BCR\/ABL regulates mammalian RecA homologs, resulting in drug resistance. Mol Cell. 2001;8: 795-806.","DOI":"10.1016\/S1097-2765(01)00357-4"},{"key":"2020021221595894800_REF13","doi-asserted-by":"crossref","unstructured":"Fischer T, Neubauer A, Mohm J, et al. chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML. Bone Marrow Transplant. 1998;21: 1029-1036.","DOI":"10.1038\/sj.bmt.1701229"},{"key":"2020021221595894800_REF14","doi-asserted-by":"crossref","unstructured":"Gale RP, Horowitz MM, Ash RC, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med. 1994;120: 646-652.","DOI":"10.7326\/0003-4819-120-8-199404150-00004"},{"key":"2020021221595894800_REF15","doi-asserted-by":"crossref","unstructured":"Majsterek I, Blasiak J, Mlynarski W, Hoser G, Skorski T. Does the bcr\/abl-mediated increase in the efficacy of DNA repair play a role in the drug resistance of cancer cells? Cell Biol Int. 2002;26: 363-370.","DOI":"10.1006\/cbir.2002.0865"},{"key":"2020021221595894800_REF16","doi-asserted-by":"crossref","unstructured":"Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)\/M phase, and protection from apoptosis. Mol Cell Biol. 2002;22: 4189-4201.","DOI":"10.1128\/MCB.22.12.4189-4201.2002"},{"key":"2020021221595894800_REF17","doi-asserted-by":"crossref","unstructured":"Jeong SJ, Jin YH, Moon CW, et al. Protein tyrosine kinase inhibitors modulate radiosensitivity and radiation-induced apoptosis in K562 cells. Radiat Res. 2001;156: 751-760.","DOI":"10.1667\/0033-7587(2001)156[0751:PTKIMR]2.0.CO;2"},{"key":"2020021221595894800_REF18","doi-asserted-by":"crossref","unstructured":"Papazisis KT, Zambouli D, Kimoundri OT, et al. Protein tyrosine kinase inhibitor, genistein, enhances apoptosis and cell cycle arrest in K562 cells treated with gamma-irradiation. Cancer Lett. 2000;160: 107-113.","DOI":"10.1016\/S0304-3835(00)00569-3"},{"key":"2020021221595894800_REF19","doi-asserted-by":"crossref","unstructured":"Riordan FA, Bravery CA, Mengubas K, et al. Herbimycin A accelerates the induction of apoptosis following etoposide treatment or gamma-irradiation of bcr\/abl-positive leukaemia cells. Oncogene. 1998;16: 1533-1542.","DOI":"10.1038\/sj.onc.1201680"},{"key":"2020021221595894800_REF20","unstructured":"Fuchs EJ, Bedi A, Jones RJ, Hess AD. Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis. Cancer Res. 1995;55: 463-466."},{"key":"2020021221595894800_REF21","doi-asserted-by":"crossref","unstructured":"van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood. 2001;98: 1532-1541.","DOI":"10.1182\/blood.V98.5.1532"},{"key":"2020021221595894800_REF22","doi-asserted-by":"crossref","unstructured":"Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol. 2001;11: R229-R232.","DOI":"10.1016\/S0960-9822(01)00112-9"},{"key":"2020021221595894800_REF23","doi-asserted-by":"crossref","unstructured":"Norbury CJ, Hickson ID. Cellular responses to DNA damage. Annu Rev Pharmacol Toxicol. 2001;41: 367-401.","DOI":"10.1146\/annurev.pharmtox.41.1.367"},{"key":"2020021221595894800_REF24","doi-asserted-by":"crossref","unstructured":"Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet. 2001;27: 247-254.","DOI":"10.1038\/85798"},{"key":"2020021221595894800_REF25","doi-asserted-by":"crossref","unstructured":"Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1: 22-33.","DOI":"10.1038\/35094000"},{"key":"2020021221595894800_REF26","doi-asserted-by":"crossref","unstructured":"de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13: 768-785.","DOI":"10.1101\/gad.13.7.768"},{"key":"2020021221595894800_REF27","doi-asserted-by":"crossref","unstructured":"Takeda N, Shibuya M, Maru Y. The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein. Proc Natl Acad Sci U S A. 1999;96: 203-207.","DOI":"10.1073\/pnas.96.1.203"},{"key":"2020021221595894800_REF28","doi-asserted-by":"crossref","unstructured":"Maru Y, Kobayashi T, Tanaka K, Shibuya M. BCR binds to the xeroderma pigmentosum group B protein. Biochem Biophys Res Commun. 1999;260: 309-312.","DOI":"10.1006\/bbrc.1999.0822"},{"key":"2020021221595894800_REF29","doi-asserted-by":"crossref","unstructured":"Nieborowska-Skorska M, Wasik MA, Slupianek A, et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J Exp Med. 1999;189: 1229-1242.","DOI":"10.1084\/jem.189.8.1229"},{"key":"2020021221595894800_REF30","doi-asserted-by":"crossref","unstructured":"Roger R, Issaad C, Pallardy M, et al. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells. Blood. 1996;87: 1113-1122.","DOI":"10.1182\/blood.V87.3.1113.bloodjournal8731113"},{"key":"2020021221595894800_REF31","doi-asserted-by":"crossref","unstructured":"Hoffmann JS, Pillaire MJ, Lesca C, et al. Fork-like DNA templates support bypass replication of lesions that block DNA synthesis on single-stranded templates. Proc Natl Acad Sci U S A. 1996;93: 13766-13769.","DOI":"10.1073\/pnas.93.24.13766"},{"key":"2020021221595894800_REF32","doi-asserted-by":"crossref","unstructured":"Biggerstaff M, Robins P, Coverley D, Wood RD. Effect of exogenous DNA fragments on human cell extract-mediated DNA repair synthesis. Mutat Res. 1991;254: 217-224.","DOI":"10.1016\/0921-8777(91)90059-X"},{"key":"2020021221595894800_REF33","doi-asserted-by":"crossref","unstructured":"Wood RD, Robins P, Lindahl T. Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts. Cell. 1988;53: 97-106.","DOI":"10.1016\/0092-8674(88)90491-6"},{"key":"2020021221595894800_REF34","doi-asserted-by":"crossref","unstructured":"Canitrot Y, Hoffmann JS, Calsou P, Hayakawa H, Salles B, Cazaux C. Nucleotide excision repair DNA synthesis by excess DNA polymerase beta: a potential source of genetic instability in cancer cells. FASEB J. 2000;14: 1765-1774.","DOI":"10.1096\/fj.99-1063com"},{"key":"2020021221595894800_REF35","unstructured":"Kuo ML, Shiah SG, Wang CJ, Chuang SE. Suppression of apoptosis by Bcl-2 to enhance benzene metabolites-induced oxidative DNA damage and mutagenesis: a possible mechanism of carcinogenesis. Mol Pharmacol. 1999;55: 894-901."},{"key":"2020021221595894800_REF36","doi-asserted-by":"crossref","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2: 561-566.","DOI":"10.1038\/nm0596-561"},{"key":"2020021221595894800_REF37","doi-asserted-by":"crossref","unstructured":"Hoeijmakers JH. Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer. 1994;30A: 1912-1921.","DOI":"10.1016\/0959-8049(94)00381-E"},{"key":"2020021221595894800_REF38","doi-asserted-by":"crossref","unstructured":"Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247: 1079-1082.","DOI":"10.1126\/science.2408149"},{"key":"2020021221595894800_REF39","doi-asserted-by":"crossref","unstructured":"Shinohara A, Ogawa T. Homologous recombination and the roles of double-strand breaks. Trends Biochem Sci. 1995;20: 387-391.","DOI":"10.1016\/S0968-0004(00)89085-4"},{"key":"2020021221595894800_REF40","doi-asserted-by":"crossref","unstructured":"Deutsch E, Dugray A, AbdulKarim B, et al. BCRABL down-regulates the DNA repair protein DNAPKcs. Blood. 2001;97: 2084-2090.","DOI":"10.1182\/blood.V97.7.2084"},{"key":"2020021221595894800_REF41","unstructured":"Gaymes TJ, Mufti GJ, Rassool FV. Myeloid leukemias have increased activity of the nonhomologous end-joining pathway and concomitant DNA misrepair that is dependent on the Ku70\/86 heterodimer. Cancer Res. 2002;62: 2791-2797."},{"key":"2020021221595894800_REF42","doi-asserted-by":"crossref","unstructured":"Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411: 366-374.","DOI":"10.1038\/35077232"},{"key":"2020021221595894800_REF43","doi-asserted-by":"crossref","unstructured":"Aboussekhra A, Biggerstaff M, Shivji MK, et al. Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell. 1995;80: 859-868.","DOI":"10.1016\/0092-8674(95)90289-9"},{"key":"2020021221595894800_REF44","doi-asserted-by":"crossref","unstructured":"Bhattacharyya NP, Ganesh A, Phear G, Richards B, Skandalis A, Meuth M. Molecular analysis of mutations in mutator colorectal carcinoma cell lines. Hum Mol Genet. 1995;4: 2057-2064.","DOI":"10.1093\/hmg\/4.11.2057"},{"key":"2020021221595894800_REF45","doi-asserted-by":"crossref","unstructured":"Canitrot Y, Lautier D, Laurent G, et al. Mutator phenotype of BCR-ABL transfected Ba\/F3 cell lines and its association with enhanced expression of DNA polymerase beta. Oncogene. 1999;18: 2676-2680.","DOI":"10.1038\/sj.onc.1202619"},{"key":"2020021221595894800_REF46","doi-asserted-by":"crossref","unstructured":"Canitrot Y, Cazaux C, Frechet M, et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc Natl Acad Sci U S A. 1998;95: 12586-12590.","DOI":"10.1073\/pnas.95.21.12586"},{"key":"2020021221595894800_REF47","doi-asserted-by":"crossref","unstructured":"Servant L, Cazaux C, Bieth A, Iwai S, Hanaoka F, Hoffmann JS. A role for DNA polymerase beta in mutagenic UV lesion bypass. J Biol Chem. 2002;277: 50046-50053.","DOI":"10.1074\/jbc.M207101200"},{"key":"2020021221595894800_REF48","doi-asserted-by":"crossref","unstructured":"Sattler M, Mohi MG, Pride YB, et al. Critical role for Gab2 in transformation by BCR\/ABL. Cancer Cell. 2002;1: 479-492.","DOI":"10.1016\/S1535-6108(02)00074-0"},{"key":"2020021221595894800_REF49","doi-asserted-by":"crossref","unstructured":"Roumiantsev S, de Aos IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr\/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001;97: 4-13.","DOI":"10.1182\/blood.V97.1.4"},{"key":"2020021221595894800_REF50","doi-asserted-by":"crossref","unstructured":"Scappini B, Onida F, Kantarjian HM, et al. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002;94: 2653-2662.","DOI":"10.1002\/cncr.10543"},{"key":"2020021221595894800_REF51","doi-asserted-by":"crossref","unstructured":"Fang G, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000;96: 2246-2253.","DOI":"10.1182\/blood.V96.6.2246"},{"key":"2020021221595894800_REF52","doi-asserted-by":"crossref","unstructured":"Kano Y, Akutsu M, Tsunoda S, et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood. 2001;97: 1999-2007.","DOI":"10.1182\/blood.V97.7.1999"},{"key":"2020021221595894800_REF53","doi-asserted-by":"crossref","unstructured":"Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood. 2000;96: 3195-3199.","DOI":"10.1182\/blood.V96.9.3195"},{"key":"2020021221595894800_REF54","doi-asserted-by":"crossref","unstructured":"Topaly J, Zeller WJ, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia. 2001;15: 342-347.","DOI":"10.1038\/sj.leu.2402041"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2632\/1691622\/h81903002632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/102\/7\/2632\/1691622\/h81903002632.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T22:07:23Z","timestamp":1581545243000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/102\/7\/2632\/17980\/p210-BCRABL-kinase-regulates-nucleotide-excision"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-10-3207","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}